Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
SPECIFIC SEROTONIN AND NORADRENALINE REUPTAKE INHIBITORS (SNRIS) - A REVIEW OF THEIR PHARMACOLOGY, CLINICAL EFFICACY AND TOLERABILITY
Autore:
BRILEY M;
Indirizzi:
INST RECH PIERRE FABRE,PARC IND CHARTEUSE F-81100 CASTRES FRANCE
Titolo Testata:
Human psychopharmacology
fascicolo: 2, volume: 13, anno: 1998,
pagine: 99 - 111
SICI:
0885-6222(1998)13:2<99:SSANRI>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
OBSESSIVE-COMPULSIVE DISORDER; 4TH GENERATION ANTIDEPRESSANT; MAJOR DEPRESSION; RAT-BRAIN; TRICYCLIC ANTIDEPRESSANTS; BIOCHEMICAL PROFILE; Z HYDROCHLORIDE; VENLAFAXINE; MILNACIPRAN; DRUG;
Keywords:
SEROTONIN UPTAKE; NORADRENALINE REUPTAKE; ANTIDEPRESSANT EFFICACY; TOLERABILITY; SEROTONIN AND NORADRENALINE REUPTAKE INHIBITORS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
75
Recensione:
Indirizzi per estratti:
Citazione:
M. Briley, "SPECIFIC SEROTONIN AND NORADRENALINE REUPTAKE INHIBITORS (SNRIS) - A REVIEW OF THEIR PHARMACOLOGY, CLINICAL EFFICACY AND TOLERABILITY", Human psychopharmacology, 13(2), 1998, pp. 99-111

Abstract

Considerable progress has been made in improving the tolerability of antidepressant drugs. The classical tricyclic antidepressants (TCA) are still, however, the standard for efficacy. The selective serotonin reuptake inhibitors are better tolerated that the tricyclics, but theirefficacy in major depression is, at best, equivalent to the earlier compounds and probably inferior in certain cases. Recently a new class of antidepressants has been developed that inhibit selectively the reuptake of both serotonin and noradrenaline with no affinity for the receptors responsible for the adverse effects of the TCAs. These compounds are referred to as the specific serotonin and noradrenaline reuptakeinhibitors or SNRIs. This article reviews the pharmacological and clinical characteristics of the two principal compounds of this class, milnacipran (Ixel(R)) and venlafaxine (Effexor(R)). This new class of antidepressants, as represented by these two compounds, presents an efficacy comparable to TCAs with a more benign side-effect profile. Certain trials suggest that they may have efficacy superior to SSRIs, especially in more severe depression, with a tolerability which is globally similar. This class therefore appears to offer a potential useful addition to the therapeutic arsenal of antidepressant drugs. (C) 1998 JohnWiley & Sons, Ltd.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 13/07/20 alle ore 11:14:42